Meta Platforms, Inc. (NASDAQ: META ) is breaking out and likely to continue to perform well in the coming months on the strength of improved engagement and revenue due to its investments in artificial intelligence. I believe the fair marketZvi provides advisory services to companies, trusts, and individuals, including consulting expert services regarding retirement and estate planning. Zvi is admitted to practice law in the state of New York, where he offers cash management, Bitcoin, and Trust Protector ser ...

Qualcomm made a takeover approach to chipmaker Intel in recent days, the Wall Street Journal reported on Friday, citing people familiar with the matter.Intel’s shares reversed course to rise 8%, while Qualcomm fell 4% in afternoon trade.Qualcomm recently approached Intel about a takeover, according to a report. REUTERSIntel has been attempting to turn its business around by focusing on its chip foundry unit and artificial intelligence processors, but its shares have plummeted in recent months as it cut jobs ...

SLB (SLB) is currently considered expensive on a relative basis, with the stock trading at an 8.26x trailing 12-month Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization (EV/EBITDA), which is at a premium compared with the broader industry average of 6.92x. A premium valuation generally indicates that the market has strong confidence in the company’s prospects. However, this necessitates scrutiny to determine if this higher price is warranted. Image Source: Zacks Investment Re ...

With the Federal Trade Commission (FTC) taking a scalpel to the pharmacy benefit managers (PBMs) of UnitedHealth Group Inc UNH, CVS Health Corp CVS and Cigna Group CI, investors are left wondering which health giant can best weather the storm.The FTC's lawsuit, targeting these companies for allegedly inflating insulin prices, could have a major ripple effect across the healthcare industry—and that means stock volatility. So, which stock looks healthier?UnitedHealth Group: Big & Bold, But Under The Microscop ...

I covered Akero Therapeutics (NASDAQ: AKRO ) in May last year when we were awaiting data from the phase 2b SYMMETRY study. Since then, two events negative for the stock have taken place. One, poor SYMMETRY data, and two, Madrigal’s (About the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.  ...

Some tickers are covered more than others on the site, so with The Undercovered Dozen our Editors highlight twelve actionable investment ideas on tickers with less coverage. These ideas can range from "boring" large caps to promising up-and-coming small caps. Specifically, the inclusion criteria for "undercovered" include: market cap greater than $100 million, more than 800 symbol page views in the last 90 days on Seeking Alpha, and fewer than two articles published in the past 30 days. Follow this account ...

文章核心观点 - Qualcomm近日接触英特尔,探讨收购事宜 [1] - 如果交易成功,将是近年来最大规模的科技并购之一 [1] - 英特尔市值约为960亿美元 [1] - 英特尔股价在2024年下跌53%,投资者对其制造和设计芯片的高成本计划表示怀疑 [1] - Qualcomm和英特尔在多个市场存在竞争,包括个人电脑和笔记本电脑芯片 [1] 根据相关目录分别进行总结 公司动态 - Qualcomm近日接触英特尔,探讨收购事宜 [1] - 如果交易成功,将是近年来最大规模的科技并购之一 [1] - 英特尔市值约为960亿美元 [1] - 英特尔股价在2024年下跌53%,投资者对其制造和设计芯片的高成本计划表示怀疑 [1] 行业竞争 - Qualcomm和英特尔在多个市场存在竞争,包括个人电脑和笔记本电脑芯片 [1]

I last wrote on ZIM Integrated Shipping Services Ltd. (NYSE: ZIM ) about two months ago (on Aug. 1, 2024, to be exact). The title of that article is "ZIM Integrated: As you can tell, our core style is to provide actionable and unambiguous ideas from our independent research. If your share this investment style, check out Envision Early Retirement. It provides at least 1x in-depth articles per week on such ideas.We have helped our members not only to beat S&P 500 but also avoid heavy drawdowns despite the ex ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vasuda Healthcare Analyt ...

Key TakeawaysNovo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results, Novo Nordisk said it would be initiating a larger Phase 2b study next year.Novo Nordisk shares were down over 5% in intraday trading Friday, though even with Friday's losses, they've gained more than 22% since the start of the year. Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study ...